• JULY 31, 2021

Windlas Biotech IPO to Hit the Market on 4 August. Key Points to Know

Manufacturer of pharmaceutical formulations, Windlas Biotech, will launch its initial public offering (IPO) next week on Wednesday, 4 August 2021.

The three-day public issue will conclude on August 6. The company has fixed the price band of the initial share sale at Rs 448-460 per share. The company plans to raise Rs 4 bn at the upper end of the price band.

This is the 31st public issue that will be launched in 2021.

Quick service restaurants (QSR) chain operator Devyani International will also be floating its IPO on the same day, 4 August.

Book running lead managers to the Windlas Biotech issue are SBI Capital Markets, DAM Capital, and IIFL Securities.

Windlas Biotech IPO Details

Issue Type Book Built Issue IPO
Face Value Rs 5 per equity share
IPO Price Rs 448 to Rs 460 per equity share
Market Lot 1 lot - 30 shares
Issue Size Rs 4 bn
Fresh Issue Rs 1.6 bn
Offer for Sale Rs 2.4 bn
Basis of Allotment Date Wednesday, August 11, 2021
IPO Listing Date Tuesday, August 17, 2021
Data Source: Company's Red Herring Prospectus

Promoter Vimla Windlass will sell 1.14 m equity shares, and investor Tano India Private Equity Fund II will offload its entire stake of 40.1 m equity shares (22% of pre-offer paid-up equity) via offer for sale (OFS).

Ashok Kumar Windlass, Hitesh Windlass, Manoj Kumar Windlass, and the Promoter Trust are the promoters of the company.

Promoter and promoter group held 78% stake in Windlas Biotech including Vimla Windlass's 7.8% shareholding.


Category-wise reserved portion

Half of the issue size that is, 50% has been reserved for qualified institutional buyers (QIBs), 35% for retail investors and the remaining 15% for non-institutional investors.

Investors can bid for a minimum of 30 shares and in multiples thereafter.

Objects of the issue

The proceeds from the fresh issue of the IPO will be utilised for purchasing of equipment required for capacity expansion of the facility at Dehradun Plant-IV and addition of injectables dosage capability at the facility at Dehradun Plant-II.

It will also be used for funding incremental working capital requirements, repayment/prepayment of certain of borrowings, and general corporate purposes.

About Windlas Biotech

Incorporated in 2001, Windlas Biotech is one of the leading companies in the pharmaceutical formulations contract development and manufacturing organisations (CDMO) segment in India.

The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.


It further sells its own branded products in the trade generics and OTC markets.

Currently, the focus of the company is to launch complex generic products in the chronic therapeutic category related to lifestyle-related disorders.

The business operates in 3 verticals - CDMO Products and services, Domestic trade generics and over-the-counter (OTC) market (nutraceutical and health supplement products), and export.

Its manufacturing facilities are located at Dehradun with an installed operating capacity of 7,063.8 m tablets/capsules, 54.5 m pouch/sachet, and 61.1 m liquid bottles.

Company's competitive strengths

  • Leading market player in the domestic pharmaceutical formulation CDMO segment.
  • Strong focus on the chronic therapeutic category.
  • State-of-the-art manufacturing facilities in Dehradun, Uttarakhand.
  • Professional and experienced promoters and a senior management team.
  • An innovative product portfolio of complex generic products.
  • Robust financial performance track record.

Financial snapshot of the company

The company has posted a CAGR (compound annual growth rate) of around 38% in top-line and 58% in gross margins for the last three fiscals.

In the last three years, the revenue from operations grew by a CAGR of 18%.

In the financial year 2019, 2020, and 2021, the revenue from operations was at Rs 3.1 bn, Rs 3.3 bn, and Rs 4.3 bn respectively.

The company has posted declining trends for the bottom line despite solid growth in the top line.


According to management, while its gross profits for all years have shown growth, accounting adjustments of gains/losses of joint ventures and impairment of goodwill has resulted in the decline in net profits.

In the process to clean its slate, it has taken a hit. It's now in the process of revamping all these which will take about two years. Thereafter it will be on a fast forward mode.

For the last three fiscals, Windlas Biotech has (on a consolidated basis) posted an earnings per share (EPS) of Rs 13.6 and a return on net worth (RoNW) of 13.3 %

The company has a market share of around 21%.

Key Parameters

(Rs bn) FY19 FY20 Dec-20
Revenues 3,072.7 3,288.5 3,207.9
Revenue Growth (%)   7%  
Expenses 2,841.9 2,992.1 2,877.9
Profit Before Tax (PBT) 761.2 246.7 135.2
Net Profit 638.2 162.1 96.7
Data Source: Company's Red Herring Prospectus (RHP)

The company does not have a formal dividend policy as of the date of this RHP.

Further, it has not declared dividends on the equity shares during the current fiscal and the last three fiscals.

It will follow a prudent dividend policy post listing based on its financial performance and future prospects.

For more details, check out Windlas Biotech's Red Herring Prospectus.

Important points to know before applying to the issue

Windlas Biotech is among the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (CDMO) industry in India in terms of revenue.

The company gets 57.9% of its business from top 10 customers, with the biggest client accounting for nearly 11% of the revenue.

Leading pharma companies like Pfizer, Sanofi India, Cadila Healthcare, Emcure Pharmaceuticals, Eris Lifesciences, Intas Pharmaceuticals, and Systopic Laboratories are some of the marquee customers of Windlas Biotech.

Also, the company has a license to manufacture around 3,279 products.

As of March 2021, the company has four plants in Dehradun with 7 bn-plus tablets/ capsules capacity.

Windlas Biotech has no listed peers to compare with.

What's the ideal IPO strategy to follow?

In the past few months, a large number of corporate houses have submitted proposals for floating IPO. A number of IPOs are also expected to hit the market soon.

As companies line up to raise funds from the market amid high valuations, investors need to consider numerous factors before investing their money in an IPO.

If you are investing in an IPO, weigh in all the positive and negative factors affecting the company.

Take a close look at the company's financials and valuations. It would give you a clear picture of what's brewing.

Happy Investing!

Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. Learn more here...

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407